A venture capital firm that specializes in early-stage in-human clinical biotech ventures are driven by a passion for groundbreaking scientific advancements that have potential to revolutionize healthcare. The firm works closely with global CROs especially those in Australia. Initial check sizes range between $100k-200k USD, which are used directly for the clinical trial, and once Phase 1b starts, the firm will continue to invest at every phase of the trials with check sizes ranging from $100k-1.5M USD. The firm is open to investing in global companies.
The firm invests in biotech companies starting at the in-human clinical trial phase. The firm is indication-agnostic and have worked with companies in CNS, oncology, cardiology, and more.
The firm prefers to take a board advisor seat or have an advisory standpoint as they like to be active investors that provide value. The firm likes to see companies with a robust IP strategy, management teams, and a clear long-term plan from an exit standpoint.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment